AOD-9604

—

evidence score

peptide

Research Only

HGH fragment 176-191Advanced Obesity Drug 9604tyr-hGH fragment

AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191 with added tyrosine at N-terminus) that retains the lipolytic (fat-burning) properties of HGH while lacking the metabolic and anabolic effects (no IGF-1 elevation, no insulin resistance, no glucose dysregulation). Originally developed by Monash University as an anti-obesity drug; Phase III clinical trials completed in 2007 showed modest fat loss benefit and exceptional safety. The FDA granted it GRAS (Generally Recognized as Safe) status. Currently research use only; Phase II/III trials showed ~14% fat mass reduction in obese subjects over 24 weeks vs placebo. Popular in gray market as a "clean" fat loss peptide that doesn't affect the GH axis.

Evidence

No score yet

Safety

Unknown safety profile

Clinical Status

No formal phase listed

Research Sync

Not synced yet

Dosing

Typical

300 mcg

250 mcgRange600 mcg

Frequency1x/day (morning, fasted)

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~30 minutes

OnsetFat mobilization effects within 15-30 minutes; body composition changes weeks to months

DurationLipolytic effect lasts 1-2 hours; cumulative with consistent use

Routes

subcutaneous_injection

intranasal

Evidence Score

—

0 studies indexed

Scoring Factors

Volume(40%)—

Quality(30%)—

Sample Size(10%)—

Consistency(10%)—

Replication(5%)—

Recency(5%)—

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

AOD-9604 is currently categorized as a peptide compound.

Evidence scoring has not been fully computed yet, so interpret this profile as preliminary.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

Beta-3 adrenergic receptor agonism increases lipolysis in adipocytes; mimics GH lipolytic domain without activating somatotropic axis; may inhibit lipogenesis

Practical Context

Strongest current signals

No indexed study summaries yet.